Generic Oncology Drugs Market 2018-2026 | Size, Share, Opportunities and Forecast | Credence Research
Apr 5, 2019
The global market for generic oncology drugs is expected to rise from US$ 17,151.0 million in 2017 to US$ 29,222.5 million by 2026, expanding at a CAGR of 6.1% from 2018 to 2026.
SANJOSE, United States - April 5, 2019 /MarketersMedia/ —
The latest market report published by Credence Research, Inc. “Global Generic Oncology Drugs Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global generic oncology drugs market is expected to reach from US$ 17,151.0 Mn in 2017 to US$ 29,222.5 Mn by 2026 expanding at a CAGR of 6.1% from 2018 to 2026.
Market Insights
According to the statistics provided by Cancer Research UK in 2018, 17 million new cases of cancer have been reported worldwide. Intellectual property policies stipulated by developed nations have caused increased drug pricing of essential medicines and, caused geographical discrimination in developing economies leading to significant rise in mortality due to lack of access to affordable medicines to treat cancer. Government healthcare agencies are adopting proactive role in promoting supportive regulatory environment for generic oncology drugs to reduce the healthcare cost burden associated with cancer treatment. Significant rise in biosimilars can prove as a major setback for the generic oncology drugs market growth.
Don't miss out on business opportunities in Generic Oncology Drugs Market
Contact Us For Customization in Type, Application & Region: https://www.credenceresearch.com/inquiry-before-buying/59653
Small molecule comprises almost 90% of the medicines currently available in the market. They are dominating the molecule type segment for generic oncology drugs market. It is popular among physicians engaged in cancer treatment owing to its impressive pharmacokinetic and pharmacodynamic drug profile. Large molecules are biologics which resembles the biomolecules present in the human body. Increased cell receptor affinity has made it popular as targeted drug therapy. It has excellent drug efficacy and safety profile with minimal side effects. Expiration of drug patent and market exclusivity will pave way for its generic version to reign the oncology drugs market.
North America is currently holding 42% market share in the regional segment for generic oncology drugs market. The chief attributes responsible for its market growth are increasing demand for generic substitution over branded oncology drugs and rising prevalence of cancer. Europe with a market share of 30% is in the second position. Domicile of key players such as Merck & Co., Mylan N.V., Novartis AG. and Teva Pharmaceutical Industries, Ltd. drive the market growth in Europe. Supportive environment provided by the European Medical Agency (EMA) bolster the market growth in European region. Asia Pacific represents 20% market share on account of significant rise in the number of patients diagnosed with cancer and increasing medical tourism.
Pharmaceutical giants having a strong foothold in the generic oncology drugs market are AstraZeneca, Plc., Bayer Healthcare AG., Celgene Corporation, F.Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Johnson and Johnson, Merck & Co., Mylan N.V., Novartis AG. and Teva Pharmaceutical Industries, Ltd.
Key Market Movements:
Significant rise in the number of patients diagnosed with cancer
Expiration of drug patent and market exclusivity of biologics will pave way for its generic version to dominate the oncology drugs market
Proactive role adopted by healthcare agencies worldwide to promote generic oncology drugs to reduce cost burden associated with cancer treatment
Get Sample(Free) @ https://www.credenceresearch.com/sample-request/59653
ToC:
Chapter 1. Preface
............
Chapter 2. Executive Summary
............
Chapter 3. Generic Oncology Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Generic Oncology Drugs Market, by Key Players, 2017
Chapter 4. Global Generic Oncology Drugs Market, by Molecule Type
4.1. Overview
4.2. Small Molecule
4.3. Large Molecule
Chapter 5. Global Generic Oncology Drugs Market, by Geography
..............
Chapter 6. Company Profiles
6.1. AstraZeneca, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Bayer Healthcare AG.
6.3. Celgene Corporation
6.4. F.Hoffman-La Roche Ltd.
6.5. GlaxoSmithKline, Plc.
6.6. Johnson and Johnson
6.7. Merck & Co.
6.8. Mylan N.V.
6.9. Novartis AG.
6.10. Teva Pharmaceutical Industries, Ltd.
..........................toc continued
Browse the full report Generic Oncology Drugs Market - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/generic-oncology-drugs-market
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com
Source: MarketersMedia
Release ID: 499131
More News
Football fixtures and results
Catch up with all the week’s football fixtures and results here.
Ainsworth: Don't come for my Gillingham players
Manager Gareth Ainsworth has told Gillingham fans to direct any criticism his way rather than towards his players.
Gills handed Trophy boost as Northampton showdown looms
Gillingham moved up into a qualifying position in the Jersey Mike’s Trophy group stage on Tuesday night, despite not playing.
Kent head coach in charge of Anderson-owned outfit
Kent head coach Adam Hollioake is to take charge of a team at the Italia T10 Cricket competition - co-owned by arguably England’s best bowler.
Smith makes amends in style as Ainsworth delivers glowing praise
Defender Andy Smith struck a late winner for Gillingham and boss Gareth Ainsworth hailed the defender as “sensational”.
Smith’s delight with Gillingham response after some harsh truths
Match-winning defender Andy Smith was delighted with Gillingham’s response to a heavy home defeat after a week of some hard truths.
Harry Waldock rises to the challenge after Gillingham recall
Harry Waldock made an instant impact on his return to the Gillingham starting line-up, showing the benefits of his hard work.
Nine wins out of nine as promotion hopefuls maintain perfect home record
Welling maintained their 100 per cent home record with a ninth successive victory to maintain the pressure on Isthmian Premier leaders Enfield.
‘I like being at home!’ Family-man Ainsworth enjoys trip back to Shrewsbury
Gareth Ainsworth put family first when he left Shrewsbury for Gillingham - and enjoyed a winning return on Saturday.
Ainsworth told Gillingham players not to fear defeat – and they delivered
Manager Gareth Ainsworth revealed the message he gave his Gillingham players before Saturday's trip after a tough week.
Report: Return joy for Gillingham boss Ainsworth
Manager Gareth Ainsworth returned to his old club and watched the Gills claim a much-needed win thanks to a late goal.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.